Sphenopalatine Ganglion Blockade: A Breakthrough for Migraine Relief

Research Summary

A recent study published in Neurologia i Neurochirurgia Polska explored the effectiveness of sphenopalatine ganglion blockade in treating episodic migraine, a condition marked by debilitating headaches and reduced quality of life. The research involved 31 patients, predominantly women, aged 22-55. Using a needleless Sphenocath applicator with 4% lidocaine, the study assessed the impact of the blockade on pain and daily functioning through various scales, including the visual analogue scale (VAS), the migraine disability assessment scale (MIDAS), and the headache impact test-6 (HIT-6). Results showed significant pain reduction and improved functioning, suggesting this method as a promising alternative or complement to traditional migraine medication.

Study Details

📄 Title: Assessment of the effectiveness of sphenopalatine ganglion blockade in the treatment of migraine.

👥 Research Team: Kierońska-Siwak S et al.

📚 Published In: Neurol Neurochir Pol

📅 Publication Date: 2025 Nov 20

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.